Find Clinical Trial

Home » Find Clinical Trials » Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of the daily dose from 150 to 300 mg per day per os). A 2-year randomised, parallel group, placebo controlled study in IPD “de novo” patients.

Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of the daily dose from 150 to 300 mg per day per os). A 2-year randomised, parallel group, placebo controlled study in IPD “de novo” patients.

← Back

Study Phase	Phase 3

Therapeutic Area	Neuropsychiatric Diseases

Indication	Parkinson's disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	PIRIBEDIL, S004200

Active Substance Code	S004200

Protocol Code	CL3-04200-006

ISRCTN Code	ISRCTN36646813

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.